Metabolic Disease News and Research

RSS

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

Scientists use highly specialized X-ray crystallography technique to solve protein structure of HIFs

In a collaborative study between Sanford Burnham Prebys Medical Discovery Institute and the Argonne National Laboratory, scientists have used a highly specialized X-ray crystallography technique to solve the protein structure of hypoxia-inducible factors (HIFs), important regulators of a tumor's response to low oxygen (hyopoxia).

6 Aug 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

Body fat can send stress signals, say University of Florida Health researchers

The brain's effect on other parts of the body has been well established. Now, a group that includes two University of Florida Health researchers has found that it's a two-way street: Body fat can send a signal that affects the way the brain deals with stress and metabolism.

24 Jul 2015

Potential molecular link identified between excess fat in the blood and blood vessel recovery in ischemia

The buildup of fat in the blood makes a bad situation worse - it not only raises a person's risk for heart attack or stroke but also impairs the growth of new blood vessels. How excess fat in the blood - a condition known as hyperlipidemia - blocks vessel growth was unclear, but new work by researchers at Temple University School of Medicine shows that a molecule known as caspase-1 plays a central role and that preventing its activity could be the key to building new blood vessels and restoring blood supply to oxygen-starved tissues.

10 Jul 2015

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

In the first study of its kind, Penn researchers have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. Mitchell Lazar, MD, PhD, Raymond Soccio, MD, PhD, and colleagues at the Perelman School of Medicine at the University of Pennsylvania, aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders.

3 Jul 2015

Small intestine causes chronic inflammation in obese patients

Obesity is caused by numerous and complex factors, some of which are as yet unsuspected. Scientists from the CNRS, INSERM, UPMC and Université Paris Descartes, working with research clinicians from Paris Public Hospitals (AP-HP) have now shown that severe obesity is accompanied by inflammation of the small intestine and enhanced immune response in that region.

22 Jun 2015

AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease.

18 Jun 2015

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

A team of researchers from the Hyperbaric Biomedical Research Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer model using a novel combination of non-toxic dietary and hyperbaric oxygen therapies.

11 Jun 2015

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism.

11 Jun 2015

Profil Institute for Clinical Research forms strategic partnership with Gubra

Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.

4 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

22 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

ZenBio, Inc. introduces GroPro™ Cell Culture Growth Supplement formulated  to replace Bovine serum

ZenBio, Inc. industry leader in robust cell-based solutions, announced today the worldwide release of a new GroPro Cell Culture Growth Supplement...

14 May 2015

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company.

6 May 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

Leukemia drug could prevent and control growth of colorectal tumours

Scientists from Nanyang Technological University (NTU Singapore) and Sweden's Karolinska Institutet, one of Europe's largest and most prestigious medical universities, have discovered that an existing chemotherapy drug used to treat leukaemia could prevent and control the growth of colorectal tumours.

3 Apr 2015

Reoccurring oxygen deprivation during pregnancy affects offspring's liver function

Sleep apnea, a disorder in which breathing repeatedly stops during sleep, is a potentially serious condition because it deprives the body of oxygen. It becomes an even more serious condition in pregnant women—who can be more prone to it—because the oxygen deprivation may affect the baby.

30 Mar 2015